SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics.

Autor: Ward, K. W.¹, Proksch, J. W.¹, Salyers, K. L.², Azzarano, L. M.¹, Morgan, J. A.¹, Roethke, T. J.¹, McSurdy-Freed, J. E.¹, Levy, M. A.³, Smith, B. R.¹

Publikováno v: Xenobiotica. Mar2002, Vol. 32 Issue 3, p221-233. 13p.

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase.

Autor: Ward, K. W., Proksch, J. W., Azzarano, L. M., Mumaw, J. A., Roethke, T. J., Stelman, G. J., Walsh, M. J., Zeigler, K. S., McSurdy-Freed, J. E., Kehler, J. R, Chokshi, J., Levy, M. A., Smith, B. R.

Publikováno v: Xenobiotica. Nov2001, Vol. 31 Issue 11, p783-797. 15p.

Nitric oxide generation by renal proximal tubules: role of nitric oxide in the cytotoxicity of lipid A.

Autor: Traylor, L A, Proksch, J W, Beanum, V C, Mayeux, P R

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; October 1996, Vol. 279 Issue: 1 p91-96, 6p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Autor: Ward KW; Preclinical Drug Discovery, Cardiovascular, Urogenitary and Oncology Center for Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA 19406, USA. keith_w_ward@gsk.com, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR

Publikováno v: Pharmaceutical research [Pharm Res] 2001 Sep; Vol. 18 (9), pp. 1336-44.